Investor Presentaiton
HANDAYUAN (Adalimumab): Entered Autoimmune Disease Area
59M RMB
Revenue recognized by Henlius in 2023
Total revenue recognized by Fosun Pharma
2 Improve patients' availability and
accessibility
Henlius' first autoimmune disease product
Covered by NRDL and completed tendering and
procurement platform listing in 29 provinces
The first phase III clinical study of adalimumab
biosimilar for psoriasis patients in China
Established the Da En Home and Zi Mian
Home, the first full cycle patient care
platforms for autoimmune diseases in China
Launched ASSC Ankylosing Spondylitis
Standardized Diagnosis and Treatment
Project together with NCRC-DID
•
Work with partners to penetrate the
market
Jiangsu Wanbang is responsible for China local sales
of HANDAYUAN. It has a sizable rheumatic immunity
business unit with experienced salesforces as well as
a mixed line sales team targeting at broad market.
Out-licensed the commercialization rights of
HANDAYUAN to Getz Pharma in 11 countries,
including Pakistan, the Philippines and Kenya, and
accelerate global footprint
阿达木单抗注射液
阿达木单抗注射液
汉达远 ®
16
Henlius
FOSUN PHARMA
(1)1至0.8m注射液
复星医药成员企业
配一次性使用无菌注射器
Amp E
和迎木鍋抗注射
Ⓒ Target: TNF-α
2024 Henlius.
Indications:
Rheumatoid arthritis
Drug Specifications:
40mg/0.8ml/bottle
•
Ankylosing spondylitis
Psoriasis
Uveitis
2 HenliusView entire presentation